Newly published guidelines from the European Society of Endocrinology and the Endocrine Society provide recommendations for managing glucocorticoid-induced adrenal insufficiency during glucocorticoid tapering in patients with inflammatory rheumatic diseases. The guidelines emphasize the significance of adrenal insufficiency risk with prolonged glucocorticoid therapy and bring attention to the complexities involved in diagnosing and managing glucocorticoid-induced adrenal insufficiency.